Lauren A Marcath1, Kelley M Kidwell2,3, Adam C Robinson1, Kiran Vangipuram1, Monika L Burness2,4, Jennifer J Griggs2,4, Catherine Van Poznak2,4, Anne F Schott2,4, Daniel F Hayes2,4, Norah Lynn Henry5, Daniel L Hertz1,2. 1. Department of Clinical Pharmacy, University of Michigan College of Pharmacy, Ann Arbor, MI 48109, USA. 2. University of Michigan Rogel Cancer Center, Ann Arbor, MI 48109, USA. 3. Department of Biostatistics, University of Michigan School of Public Health, Ann Arbor, MI 48109, USA. 4. Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Medical School, Ann Arbor, MI 48109, USA. 5. Department of Internal Medicine, Division of Oncology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA.
Abstract
AIM: First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [Tc >0.05]). Second, screen additional pharmacogenes for associations with Tc >0.05. Methods: Pharmacogene panel genotypes were translated into genetic phenotypes for associations with Tc >0.05 (n = 58). RESULTS: Patients with predicted low-activity CYP2C8 had shorter Tc >0.05 after adjustment for age, body surface area and race (9.65 vs 11.03 hrs, β = 5.47, p = 0.02). This association was attributed to CYP2C8*3 (p = 0.006), not CYP2C8*4 (p = 0.58). Patients with predicted low-activity SLCO1B1 had longer Tc >0.05 (12.12 vs 10.15 hrs, β = 0.85, p = 0.012). CONCLUSION: Contrary to previous publications, CYP2C8*3 may confer increased paclitaxel metabolic activity. SLCO1B1 and CYP2C8 genotype may explain some paclitaxel pharmacokinetic variability.
AIM: First, evaluate if patients carrying putatively diminished activity CYP2C8 genotype have longer paclitaxel exposure (e.g., time above threshold concentration of 0.05 μM [Tc >0.05]). Second, screen additional pharmacogenes for associations with Tc >0.05. Methods: Pharmacogene panel genotypes were translated into genetic phenotypes for associations with Tc >0.05 (n = 58). RESULTS:Patients with predicted low-activity CYP2C8 had shorter Tc >0.05 after adjustment for age, body surface area and race (9.65 vs 11.03 hrs, β = 5.47, p = 0.02). This association was attributed to CYP2C8*3 (p = 0.006), not CYP2C8*4 (p = 0.58). Patients with predicted low-activity SLCO1B1 had longer Tc >0.05 (12.12 vs 10.15 hrs, β = 0.85, p = 0.012). CONCLUSION: Contrary to previous publications, CYP2C8*3 may confer increased paclitaxel metabolic activity. SLCO1B1 and CYP2C8 genotype may explain some paclitaxel pharmacokinetic variability.
Authors: Namrata Bahadur; Julian B S Leathart; Elaine Mutch; Dorothy Steimel-Crespi; Stuart A Dunn; Ron Gilissen; Jos Van Houdt; Jan Hendrickx; Geert Mannens; Hilde Bohets; Faith M Williams; Martin Armstrong; Charles L Crespi; Ann K Daly Journal: Biochem Pharmacol Date: 2002-12-01 Impact factor: 5.858
Authors: Umit Yasar; Stefan Lundgren; Erik Eliasson; Anna Bennet; Björn Wiman; Ulf de Faire; Anders Rane Journal: Biochem Biophys Res Commun Date: 2002-11-22 Impact factor: 3.575
Authors: Daniel L Hertz; Kelley M Kidwell; Kiran Vangipuram; Feng Li; Manjunath P Pai; Monika Burness; Jennifer J Griggs; Anne F Schott; Catherine Van Poznak; Daniel F Hayes; Ellen M Lavoie Smith; N Lynn Henry Journal: Clin Cancer Res Date: 2018-04-27 Impact factor: 12.531
Authors: Anja Henningsson; Sharon Marsh; Walter J Loos; Mats O Karlsson; Adam Garsa; Klaus Mross; Stephan Mielke; Lucia Viganò; Alberta Locatelli; Jaap Verweij; Alex Sparreboom; Howard L McLeod Journal: Clin Cancer Res Date: 2005-11-15 Impact factor: 12.531
Authors: Stephan Mielke; Alex Sparreboom; Seth M Steinberg; Hans Gelderblom; Clemens Unger; Dirk Behringer; Klaus Mross Journal: Clin Cancer Res Date: 2005-07-01 Impact factor: 12.531
Authors: Markus Joerger; Alwin D R Huitema; Desiree H J G van den Bongard; Jan H M Schellens; Jos H Beijnen Journal: Clin Cancer Res Date: 2006-04-01 Impact factor: 12.531
Authors: Henrik Gréen; Peter Söderkvist; Per Rosenberg; Rajaa A Mirghani; Per Rymark; Elisabeth Avall Lundqvist; Curt Peterson Journal: Basic Clin Pharmacol Toxicol Date: 2008-12-16 Impact factor: 4.080
Authors: Keneuoe Cecilia Nthontho; Andrew Khulekani Ndlovu; Kirthana Sharma; Ishmael Kasvosve; Daniel Louis Hertz; Giacomo Maria Paganotti Journal: Pharmgenomics Pers Med Date: 2022-06-21
Authors: Li Chen; Ciao-Sin Chen; Yihan Sun; N Lynn Henry; Kathleen A Stringer; Daniel L Hertz Journal: Cancer Chemother Pharmacol Date: 2021-06-05 Impact factor: 3.288
Authors: Cathrine F Hjorth; Per Damkier; Tore B Stage; Søren Feddersen; Stephen Hamilton-Dutoit; Mikael Rørth; Bent Ejlertsen; Timothy L Lash; Thomas P Ahern; Henrik T Sørensen; Deirdre Cronin-Fenton Journal: Breast Cancer Res Treat Date: 2022-04-30 Impact factor: 4.624
Authors: Jose J G Marin; Maria A Serrano; Maria J Monte; Anabel Sanchez-Martin; Alvaro G Temprano; Oscar Briz; Marta R Romero Journal: Int J Mol Sci Date: 2020-04-20 Impact factor: 5.923